Data presented at AMCP Nexus 2023. European Headquarters. : Nasdaq Theratechnologies Inc. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . 71. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. Stockhouse. Stockhouse. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. 54% and a negative trailing twelve-month return on equity of. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. com uses cookies on this site. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. During the last trading day the stock fluctuated 4. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. 1300 (+9. com. Theratechnologies Inc. NCU. . GlobeNewswire. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. 06 million, an increase of. 514-336-7800. These pharmaceuticals. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. 1-438. T. is a speaker and consultant of Theratechnologies. MONTREAL, Sept. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. com. We also use them to share. Proceeds to Be Used to Redeem All of the Outstanding 5. com uses cookies on this site. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. Theratechnologies inc. MONTREAL, Oct. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. -4. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. - 2023 Q3 positive adjusted EBITDA to be. com uses cookies on this site. 65 per cent to C$1. stock news by MarketWatch. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. The financial results presented in this press release are taken from the. lgibson. Stockhouse. About Theratechnologies Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy ageing and an improved quality of life among HIV patients. 40 f102M H1. com. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. com. By continuing to use our service, you agree to our use of cookies. MONTREAL, Feb. TH | September 26, 2023. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. We also use them to share usage. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. We also use them to share. com uses cookies on this site. Stockhouse. The company was. Theratechnologies Inc. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. 81 million for the quarter. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business. com uses cookies on this site. TH | Complete Theratechnologies Inc. 67, which is an increase of 1,144. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Message Board Total Posts: 4. Further. com uses cookies on this site. 's motion for leave to commence. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. 9%, while the Biotechs industry saw earnings growing at 17. Q4 2022 consolidated revenue growth of 14. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Montréal, Québec, Canada . The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. znewcar1. 25. was a. com uses cookies on this site. Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. It's a different kind of fat that may require a different type of treatment. By continuing to use our service, you agree to our use of cookies. Stockhouse. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. ir@theratech. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance; FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash. MONTREAL, Nov. By continuing to use our service, you agree to our use of cookies. Q3 2023 consolidated revenue of $20. Further. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Nov. Stockhouse. 51 to 200 Employees. 4% from the stock's current price. MONTREAL, Oct. MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. stock news by MarketWatch. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to analyze our traffic. communications@theratech. Who is Theratechnologies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. TORONTO, Sept. We currently market prescription products for people with HIV in the United States. However, it did not meet the equivalence limits of 0. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, Oct. Patient assistance: 833-238-4372. 23) diluted earnings per. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Cookies are used to offer you a better browsing experience and to analyze our traffic. 63. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. Stockhouse. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. By continuing to use our service, you agree to our use of cookies. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 1-514-336-7800. 46. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. VANCOUVER, British Columbia, Nov. Theratechnologies Inc. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. (THTX) Stock Price, Quote & News - Stock Analysis -20. Theratechnologies Inc. 3. Theratechnologies last announced its earnings data on September 26th, 2023. 4%. (TH. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for. Website. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. Senior Director, Investor Relations. com uses cookies on this site. Real-time discussion about Theratechnologies Inc. com uses cookies on this site. T. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. We also use them to share usage information with our partners. Cookies are used to offer you a better browsing experience and to analyze our traffic. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. These companies provide a lot of detail to the OTC Markets Group including audited financials. Montréal, Québec, Canada . $103. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug. Headquarters. Watch list NEW Set a price target alert After Hours Last. com. org. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. BioSyent then managesthese products through the regulatory process and product registration (approval); and once approved, BioSyent markets these products throughout Canada. Theratechnologies Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). 0. Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. 4%. (THTX) stock. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. 71%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. View real-time stock prices and stock quotes for a full financial overview. Theratechnologies Inc. com uses cookies on this site. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. com. MONTREAL, Feb. 72%. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. com. By continuing to use our service, you agree to our use of cookies. Stockhouse. Theratechnologies to Announce Financial Results for Its First Quarter 2022. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. Theratechnologies (TSX:TH) has announced a loan of up to US$100M from Marathon Asset Management. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. Track Theratechnologies Inc. Stockhouse. com uses cookies on this site. We also use them to share usage information with our partners. 00 to $36. THERATECHNOLOGIES INC. Elif McDonald - Senior Director, Investor Relations. By continuing to use our service, you agree to our use of cookies. 00%. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. com. . We also use them to share usage. - Q3 2022 Consolidated. By continuing to use our service, you agree to our use of cookies. Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. com. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. By continuing to use our service, you agree to our use of cookies. (2021-12-06 | TSX:TH) Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV. home message. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. Find the latest Theratechnologies Inc. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis. We currently market prescription products for people with. Unveiling Silvercorp's golden potential at the Ying Mining District. T. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. . By Nick Paul Taylor Jul 12, 2023 8:57am. B2Gold Declares Fourth Quarter 2023 Dividend. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. - Q3 2022 Consolidated Revenue Growth of 17% to $20. The money will be used to grow the company’s FDA-approved drugs, Egrifta SV (tesamorelin), used for the reduction of excess. com. Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH). com uses cookies on this site. (THTX) stock. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TH1902, the leading product candidate derived from the SORT1+ Technology, is a first-in-class peptide-drug. TH Stock Message Board for Investors. 04) earnings per share (EPS) for the quarter. com uses cookies on this site. com uses cookies on this site. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. The company had revenue of $20. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. 49%) At close: 04:00PM EST 1. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Vice President, Communications and Corporate Affairs. 17. The abstract and poster can be found on Theratechnologies’ website. By continuing to use our service, you agree to our use of cookies. Theratechnologies Inc. Stock analysis for Theratechnologies Inc (TH:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. 68 to a day high of $1. T. ( THTX 3. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. We also use them to share usage. . Losses were -47. TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. 02%. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City Stockhouse. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Announces 1-for-4 Reverse Stock Split. By continuing to use our service, you agree to our use of cookies. . (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its Phase 1 oncology. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. Cookies are used to offer you a better browsing experience and to analyze our traffic. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. 86 million for the quarter. This suggests a possible upside of 2,471. Investor Relations. Stockhouse. 2% for this period. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. Investor inquiries: Elif McDonald. TH 48% v4,15M c1. [email protected] Inc: Overview. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. m. Cookies are used to offer you a better browsing experience and to. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. : Renegotiated Lease to Generate Substantial Annual Savings. m. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical. US Headquarters. (2020-10-16 | TSX:TH) Theratechnologies Appoints Two New Board Members. Competitors: Unknown. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. 89 52. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. MONTREAL, Jan. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Montreal-based biopharmaceutical company Theratechnologies Inc. Stockhouse. The company develops treatments for lipodystrophy . The company reported ($0. Cookies are used to offer you a better browsing experience and to analyze our traffic. 31K. By continuing to use our service, you agree to our use of cookies. 124. T. One reason for that is that this tier does not include penny stocks. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. com uses cookies on this site. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. Investor Relations. com uses cookies on this site. - Cash, bonds and money market funds of US$22. 51 S1. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. com uses cookies on this site. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. Gary Littlejohn. Stockhouse. com uses cookies on this site. Stockhouse. 1M. Cookies are used to offer you a better browsing experience and to analyze our traffic. TH | September 5, 2023. 5%. MONTREAL, Oct. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. Cookies are used to offer you a better browsing experience and to analyze our traffic. Company Description: Theratechnologies is pepped up on peptides. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 28 $1. We currently market prescription products for people with HIV in the United States.